Enliven Therapeutics Inc.

NASDAQ: ELVN · Real-Time Price · USD
20.24
0.47 (2.38%)
At close: Aug 15, 2025, 3:59 PM
20.22
-0.10%
After-hours: Aug 15, 2025, 06:46 PM EDT

Enliven Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Cash & Equivalents
119.44M 101.7M 124.12M 100.62M 96.87M 149.22M 100.19M 73.85M 125.72M 292.1M 88.2M 86.16M 30.43M 36.48M 110.02M 75.3M 48.04M 53.44M
Short-Term Investments
371.07M 187.85M 189.32M 191.21M 215.52M 171.34M 153.01M 189.63M 152.15M n/a n/a 6.81M 29.91M 36.42M 41.97M 27.54M 18.73M 22.15M
Long-Term Investments
n/a n/a n/a n/a n/a n/a n/a 54K 54K 54K n/a n/a 175K 175K 41.97M 175K 175K 88K
Other Long-Term Assets
7.24M 7.2M 7.17M 7.8M 8.13M 4.65M 4.65M 4.18M 3.93M 3.4M 807K 1.01M n/a n/a -40.26M n/a n/a 220K
Receivables
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Inventory
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Current Assets
5.12M 4.76M 4.69M 5.16M 5.74M 10M 12.95M 5.13M 5.31M 5.9M 1.44M n/a 3.92M 5.63M n/a 3.16M 4.59M 4.77M
Total Current Assets
495.62M 294.32M 318.13M 297M 318.13M 337.2M 266.15M 268.61M 283.18M 298M 89.64M 88.23M 64.26M 78.53M 110.67M 106M 71.36M 80.36M
Property-Plant & Equipment
1.03M 1.05M 458K 630K 791K 924K 1.06M 1.2M 1.34M 1.4M 1.52M 1.55M 235K 2.9M 954K 855K 936K 1.02M
Goodwill & Intangibles
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Total Long-Term Assets
8.27M 8.25M 7.63M 8.43M 8.92M 5.58M 5.72M 5.43M 5.33M 4.86M 2.32M 2.57M 410K 3.07M 2.66M 1.03M 1.11M 1.33M
Total Assets
503.89M 302.57M 325.76M 305.43M 327.04M 342.78M 271.87M 274.04M 288.5M 302.87M 91.96M 90.8M 64.67M 81.6M 113.33M 107.03M 72.47M 81.69M
Account Payables
2.35M 1.56M 1.34M 1.02M 1.08M 2.73M 532K 1.49M 2.84M 5.86M 3.44M 2.99M 1.14M 1.88M 2.52M 2.48M 2.63M 3M
Deferred Revenue
n/a n/a n/a n/a n/a n/a n/a n/a 5.63M n/a -323K n/a n/a n/a 2.7M n/a n/a n/a
Short-Term Debt
n/a 365K n/a 85K 169K 252K 335K 332K n/a n/a n/a n/a 445K 508K n/a 250K 254K 257K
Other Current Liabilities
15.21M 1.79M 4.81M 3.61M 9.09M 19.99M 21.36M 36K 4.2M 3.72M 1.64M 1.08M 1.05M 3.7M 233K 2.9M 3M 1.58M
Total Current Liabilities
15.21M 13.97M 15.91M 17.03M 22.11M 25.03M 25.89M 12.08M 9.15M 10.94M 1.83M 8.33M 3.3M 7.22M 5.75M 7.19M 6.97M 5.5M
Long-Term Debt
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 466K 528K 590K
Other Long-Term Liabilities
204K 302K n/a n/a 6K 34K 67K 214K 360K 508K 150.41M 150.56M 1.58M n/a 150.46M -466K -528K -590K
Total Long-Term Liabilities
204K 302K n/a n/a 6K 34K 67K 214K 360K 508K 150.41M 150.56M 1.58M 1.97M 150.46M 466K 528K 590K
Total Liabilities
15.41M 14.27M 15.91M 17.03M 22.11M 25.07M 25.96M 12.29M 9.51M 11.45M 1.83M 158.89M 3.3M 9.19M 156.22M 7.65M 7.5M 6.09M
Total Debt
n/a 365K n/a 85K 169K 252K 335K 332K 329K 326K 323K 320K 445K 2.48M 159K 716K 782K 847K
Common Stock
59K 49K 49K 47K 47K 47K 41K 41K 41K 41K 27K 1K 27K 27K 1K 27K 19K 18K
Retained Earnings
-297.35M -272.02M -243.47M -220.29M -197.14M -177.19M -154.45M -135.08M -114.31M -97.59M -146.01M -73.31M -173.59M -162.14M -45.2M -133.18M -119.53M -106.37M
Comprehensive Income
-177K -16K 55K 242K -139K -53K 141K -147K -111K -0.00 -176.75K -4K -35K -51K -16K -2K n/a 1K
Shareholders Equity
488.47M 288.3M 309.85M 288.4M 304.93M 317.71M 245.91M 261.75M 278.99M 291.42M 90.13M -68.1M 61.36M 72.41M -42.89M 99.37M 64.97M 75.59M
Total Investments
n/a 187.85M 189.32M 191.21M 215.52M 171.34M 153.01M 189.63M 152.15M 54K n/a 6.81M 30.08M 36.59M 41.97M 27.72M 18.91M 22.24M